share_log
Breakings ·  Nov 20 05:03
Viking Therapeutics Presents Results From Phase 2B Voyage Study of Vk2809 in Biopsy-Confirmed Nash/Mash at the 75TH Liver Meeting® 2024
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment